2 Information about Palforzia

Marketing authorisation indication

2.1 Palforzia is indicated 'for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia may be continued in patients aged 18 years or older. Palforzia should be used in conjunction with a peanut-avoidant diet'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics for palforzia.


2.3 The list price of Palforzia is £10.12 per day. A flat price is applied for each Palforzia dose (range 0.5 mg to 300 mg).

  • National Institute for Health and Care Excellence (NICE)